Loading…
MOLN
Molecular Partners AG
NASDAQ· Healthcare· Biotechnology· CUSIP 60853G106
$4.50-3.28%Price as of Aug 29, 18:41 UTC · updated once a day, after the close
Key metrics
- Market cap
- $172.37M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.4x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.68
- ROE
- -61.97%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.68
- 52-week high
- $5.36
- 52-week low
- $3.53
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -76.9% over 5Y.
today you would have $219.28▼ -78.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $4.36 | $4.75 | $4.18 | $6.55 | |
| P/E | — | — | — | — | 1.9x |
| P/S | 19.5x | — | 35.2x | 19.5x | 1.2x |
| P/B | 1.1x | 2.0x | 1.2x | 0.8x | 1.0x |
| EPS | -$1.65 | -$1.59 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| LFCRLifecore Biomedical Inc de | $4.54 | — | — | — | — | $171.85M |
| OGIOrganigram Global Inc | $1.22 | 2.8x | 0.5x | — | 17.56% | $171.32M |
| QSIQuantum-Si Inc | $0.78 | — | 0.9x | — | -49.11% | $170.73M |
| ZJYLJin Medical International Ltd. | $2.34 |
About the company
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
- 134
- Schlieren, Switzerland
Company description provided by Yahoo Finance.